Loading...
•
Sep 30, 2025
Pediatrix Q3 2025 Earnings Report
Pediatrix reported higher-than-expected earnings in Q3 2025, with strong net income and growth in same-unit revenue driven by improved collections and patient acuity.
Key Takeaways
Pediatrix Medical Group delivered strong Q3 results, surpassing internal expectations. The company benefited from favorable reimbursement dynamics and higher patient acuity, resulting in significant growth in same-unit revenue and profitability.
Revenue reached $492.9 million, down from $511.2 million YoY due to practice dispositions, but same-unit revenue grew 8.0%
Net income jumped to $71.7 million, compared to $19.4 million in the prior-year quarter
Adjusted EPS increased to $0.67 from $0.44 a year earlier
Raised full-year 2025 Adjusted EBITDA guidance to a range of $270 million to $290 million
Forward Guidance
Pediatrix raised its full-year 2025 Adjusted EBITDA forecast to a range of $270–$290 million, driven by better-than-expected performance in Q3.
Positive Outlook
- Raised FY25 Adjusted EBITDA outlook to $270M–$290M
- Strong same-unit revenue growth supported by improved collections
- Higher patient acuity in hospital-based services, especially neonatology
- Favorable payor mix boosted reimbursement
- Cost reductions from practice dispositions contributed to margin improvement
Challenges Ahead
- Total revenue declined YoY due to practice dispositions
- Office-based patient volume saw a slight decline (-0.6%)
- G&A expenses increased YoY due to incentive compensation
- Continued restructuring and transition costs incurred
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...